EMG
MYGN icon

Ellington Management Group’s Myriad Genetics MYGN Stock Holding History

Ellington Management Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-13,100
Closed -$252K – 816
2017
Q1 		$252K Buy
+13,100
New +$232K 0.01% 510
2015
Q4 		– Sell
-7,800
Closed -$292K – 730
2015
Q3 		$292K Buy
+7,800
New +$277K 0.08% 422
2014
Q1 		– Sell
-17,200
Closed -$361K – 716
2013
Q4 		$361K Sell
17,200
-18,800
-52% -$475K 0.13% 262
2013
Q3 		$846K Buy
36,000
+1,800
+5% +$51.1K 0.16% 152
2013
Q2 		$919K Buy
+34,200
New +$991K 0.17% 127

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Ellington Management Group's MYGN Position: Q2 2017 in Review

Ellington Management Group sold out of Myriad Genetics (MYGN) in Q2 2017, closing a stake of 13,100 shares — an estimated $252K sold.

Ellington Management Group first reported a position in MYGN in Q2 2013 and held it in 5 quarters. The position peaked at $919K in Q2 2013. 239 funds tracked by Wall St. Rank hold MYGN as of Q2 2017.

  • Ellington Management Group reported no remaining Myriad Genetics position as of Q2 2017 after selling out during the quarter.
  • Ellington Management Group sold 13,100 Myriad Genetics shares in Q2 2017, an estimated $252K.
  • Ellington Management Group first reported a position in Myriad Genetics in Q2 2013 and held it in 5 quarters.
  • Ellington Management Group's Myriad Genetics position peaked at $919K in Q2 2013.
  • 239 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2017.

Based on Ellington Management Group's 13F filing for Q2 2017, filed 14 Aug 2017.